RT Journal Article
SR Electronic
T1 Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.11.22272784
DO 10.1101/2022.04.11.22272784
A1 Peter J. Halfmann
A1 Nicholas R. Minor
A1 Luis A. Haddock III
A1 Robert Maddox
A1 Gage K. Moreno
A1 Katarina M. Braun
A1 David A. Baker
A1 Kasen K. Riemersa
A1 Ankur Prasad
A1 Kirsten J. Alman
A1 Matthew C. Lambert
A1 Kelsey Florek
A1 Allen Bateman
A1 Ryan Westergaard
A1 Nasia Safdar
A1 Dave R. Andes
A1 Yoshihiro Kawaoka
A1 Madiha Fida
A1 Joseph D. Yao
A1 Thomas C. Friedrich
A1 David H. O’Connor
YR 2022
UL http://medrxiv.org/content/early/2022/04/12/2022.04.11.22272784.abstract
AB Prolonged infections in immunocompromised individuals may be a source for novel SARS-CoV-2 variants, particularly when both the immune system and antiviral therapy fail to clear the infection, thereby promoting adaptation. Here we describe an approximately 16-month case of SARS-CoV-2 infection in an immunocompromised individual. Following monotherapy with the monoclonal antibody Bamlanivimab, the individual’s virus was resistant to this antibody via a globally unique Spike amino acid variant (E484T) that evolved from E484A earlier in infection. With the emergence and spread of the Omicron Variant of Concern, which also contains Spike E484A, E484T may arise again as an antibody-resistant derivative of E484A.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institutes of Allergy and Infectious Diseases Center for Research on Influenza Pathogenesis (HHSN272201400008C), the Center for Research on Influenza Pathogenesis and Transmission (CRIPT) (75N93021C00014), and by CDC Contract #75D30121C11060. Consensus sequence data was processed using the compute resources and assistance of the UW-Madison Center For High Throughput Computing (CHTC), which is supported by UW-Madison, the Advanced Computing Initiative, the Wisconsin Alumni Research Foundation, the Wisconsin Institutes for Discovery, and the National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Collection and testing of biological specimens and protected health information were performed in concordance with the University of Wisconsin IRB # 2021-0076 following informed consent from the patient.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll scripts, consensus sequence data, and sequencing read data used in the writing of this manuscript can be found at https://github.com/dholab/E484T-visualizations. Additional data from intermediate stages of our analysis are available upon reasonable request to the authors. https://github.com/dholab/E484T-visualizations